Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach
Vincenzo Mazzaferro – 24 December 2015
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older
Sammy Saab, Sarah H. Park, Masashi Mizokami, Masao Omata, Alessandra Mangia, Ed Eggleton, Yanni Zhu, Steven J. Knox, Phil Pang, Mani Subramanian, Kris Kowdley, Nezam H. Afdhal – 24 December 2015 – Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of <65 years versus ≥65 years among subjects enrolled in phase 3 trials.
Prediction of bleeding in cirrhosis patients: Is the forecast any clearer?
Nicolas M. Intagliata, Stephen H. Caldwell, Robert J. Porte, Ton Lisman – 24 December 2015
Reply
Lesley De Pietri, Marcello Bianchini, Guadalupe Garcia‐Tsao, Erica Villa – 24 December 2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
Eric Lawitz, Gary Matusow, Edwin DeJesus, Eric M. Yoshida, Franco Felizarta, Reem Ghalib, Eliot Godofsky, Robert W. Herring, Gary Poleynard, Aasim Sheikh, Hillel Tobias, Marcelo Kugelmas, Ronald Kalmeijer, Monika Peeters, Oliver Lenz, Bart Fevery, Guy De La Rosa, Jane Scott, Rekha Sinha, James Witek – 24 December 2015 – Hepatitis C virus (HCV)–infected patients with cirrhosis are historically a difficult‐to‐treat population and are at risk of hepatic decompensation.
CD14+ regulatory dendritic cells in patients with hepatocellular carcinoma and cirrhosis
Shiroh Tanoue, David E. Kaplan – 24 December 2015
Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?
Enrico Galmozzi, Roberta D'Ambrosio – 24 December 2015
Genetic variation in STAT4 predicts response to interferon‐α therapy for hepatitis B e antigen‐positive chronic hepatitis B
De‐Ke Jiang, Xiaopan Wu, Ji Qian, Xiao‐Pin Ma, Jingmin Yang, Zhuo Li, Runhua Wang, Li Sun, Fang Liu, Pengyin Zhang, Xilin Zhu, Jia Wu, Kangmei Chen, Carly Conran, S. Lilly Zheng, Daru Lu, Long Yu, Ying Liu, Jianfeng Xu – 24 December 2015 – Interferon (IFN)‐α is a first‐line therapy for chronic hepatitis B (CHB) patients but only initiates a response in a minority of patients. A genetic variant, rs7574865 in STAT4, was recently reported to be associated with risk of developing CHB and hepatitis B virus‐related hepatocellular carcinoma.
Toward new standards for noninvasive measuring of portal pressure?
Søren Møller – 24 December 2015
Acetyl‐coenzyme A carboxylase alpha promotion of glucose‐mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients
Ming‐Da Wang, Han Wu, Gong‐Bo Fu, Hui‐Lu Zhang, Xu Zhou, Liang Tang, Li‐Wei Dong, Chen‐Jie Qin, Shuai Huang, Ling‐Hao Zhao, Min Zeng, Meng‐Chao Wu, He‐Xin Yan, Hong‐Yang Wang – 23 December 2015 – Solid tumors often suffer from suboptimal oxygen and nutrient supplies. This stress underlies the requirement for metabolic adaptation. Aberrantly activated de novo lipogenesis is critical for development and progression of human hepatocellular carcinoma (HCC).